TransCode Therapeutics, Inc. (RNAZ) Q1 2024 Annual Earnings
RNAZ·Reported May 15, 2024·Before market open
Diluted EPS came in at $-21.45, beat the $-23.10 consensus by $1.65.
Diluted EPS
$-21.45beat by $1.65
Consensus: $-23.10
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about TransCode Therapeutics, Inc.'s Q1 2024 earnings report.
TransCode Therapeutics, Inc. (RNAZ) reported Q1 2024 earnings on May 15, 2024 before market open.
TransCode Therapeutics, Inc. reported diluted EPS of $-21.45 for Q1 2024.
EPS beat the consensus estimate of $-23.10 by $1.65.
You can read the 10-K periodic report (0001410578-24-000413) directly on SEC EDGAR. The filing index links above go to sec.gov.